TORONTO, June 27, 2019 /CNW/ - Acerus Pharmaceuticals
Corporation ("Acerus") (TSX:ASP) today announced the voting
results from its annual meeting of shareholders held on
June 27, 2019 in Toronto, Ontario. The total number of shares
represented in person or by proxy at the meeting was 118,253,703,
representing 45.27% of the total issued and outstanding
Acerus shares.
Election of Directors
The six (6) candidates nominated for election to the Acerus
board of directors and listed in Acerus' management information
circular dated May 15, 2019, were
elected by a majority of the shareholders present in person or
represented by proxy at the meeting. The voting results are
as follows:
|
Name
|
Votes
For (%)
|
Votes
Withheld (%)
|
|
Ian
O. Ihnatowycz
|
117,473,603
(99.34%)
|
780,100
(0.66%)
|
|
Norma Beauchamp
|
118,240,703
(99.99%)
|
13,000
(0.01%)
|
|
Borys Chabursky
|
114,699,103
(96.99%)
|
3,554,600
(3.01%)
|
|
Stephen Gregory
|
113,949,603
(96.36%)
|
4,304,100
(3.64%)
|
|
J.
Mark Lievonen
|
118,213,103
(99.97%)
|
40,600
(0.03%)
|
|
Edward Gudaitis
|
117,462,603
(99.33%)
|
791,100
(0.67%)
|
Appointment of Auditors
Acerus announced today that its shareholders have approved the
re‐appointment of PricewaterhouseCoopers LLP as the Auditor of
Acerus to hold office until the next annual meeting of
shareholders.
About Acerus
Acerus Pharmaceuticals Corporation is a Canadian-based specialty
pharmaceutical company focused on the commercialization and
development of innovative prescription products that improve
patient experience, with a primary focus in the field of men's
health. Acerus commercializes its products via its own salesforce
in Canada, and through a global
network of licensed distributors in the U.S. and other
territories.
Acerus' shares trade on TSX under the symbol ASP and on OTCQB
under the symbol ASPCF. For more information, visit
www.aceruspharma.com and follow us on Twitter and LinkedIn.
Notice regarding forward‐looking statements
Information in this press release that is not current or
historical factual information may constitute forward‐looking
information within the meaning of securities laws. Implicit in this
information are assumptions regarding our future operational
results. These assumptions, although considered reasonable by the
company at the time of preparation, may prove to be incorrect.
Readers are cautioned that actual performance of the company is
subject to a number of risks and uncertainties and could differ
materially from what is currently expected as set out above. For
more exhaustive information on these risks and uncertainties you
should refer to our annual information form dated March 4, 2019 that is available at www.sedar.com.
Forward‐looking information contained in this press release is
based on our current estimates, expectations and projections, which
we believe are reasonable as of the current date. You should not
place undue importance on forward‐looking information and should
not rely upon this information as of any other date. While we may
elect to, we are under no obligation and do not undertake to update
this information at any particular time, whether as a result of new
information, future events or otherwise, except as required by
applicable securities law.
SOURCE Acerus Pharmaceuticals Corporation
